tirzepatide adolescent obesity trial for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Tirzepatide for Obesity Treatment and

placebo, N=113), the adverse reactions reported regardless of investigator assessment of causality in 5% of patients treated with sitagliptin and more commonly than in patients treated with placebo were: hypoglycemia (Table 3) and headache (6.9%, 2.7%)

While many patients harmed by GLP-1 drugs such as Ozempic, Wegovy, or Mounjaro may join a class action lawsuit or multidistrict litigation, others may benefit more from filing an individual lawsuit

Quality Assurance & Batch Documentation Current USCL 070626 documents are centralized below and retained in the COA, HPLC, and MS tabs

Elle published an expos about bad actors and loose regulation in the medical spa industry

PMID: 33 HarrisRAJoshiMJeoungNHObayashiM